ICMT and Hutchinson-Gilford progeria syndrome: Nonetheless, our study takes two important steps in the preclinical validation of ICMT as a potential drug target, and thereby raises hopes that ICMT inhibition could be an effective strategy for treating children with HGPS and progeroid disorders resulting from ZMPSTE24 deficiency (Michaelis and Hrycyna, 2013).